Kristijan H. Kahler, PhD, RPh, Executive Director, Outcomes Research Methods & Analytics, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, ISPOR Washington DC, 2012.
Home » Links » Is it possible to efficiently generate and interpret CER for newly marketed drugs in time?
